Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)

9 Months Ended

Sep. 30, 2018

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements

Disaggregation Of Revenue

In thousands of US dollars ($)		Three Months Ended September 30, 2018						Nine Months Ended September 30, 2018
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	68	$	—	$	68	$	205	$	—	$	205
Concentrate Products
Product Sales – Point-in-time		16,099		13,208		2,891		44,815		38,536		6,279
License Fee – Point-in-time		505		505		—		1,514		1,514		—
Total Concentrate Products		16,604		13,713		2,891		46,329		40,050		6,279
Net Revenue	$	16,672	$	13,713	$	2,959	$	46,534	$	40,050	$	6,484

Contract Balances

In thousands of US dollars ($)	September 30, 2018		December 31, 2017
Receivables, which are included in "Trade and other receivables"	$	7,593	$	5,544
Contract liabilities	$	15,005	$	16,723

Summary of potentially dilutive securities

	As of September 30,
	2018		2017
Options to purchase common stock		8,048,105		7,326,501
Unvested restricted stock awards		-		480,000
Unvested restricted stock units		1,293,750		-
		9,341,855		7,806,501